European Commission appoints the new members of the European Group on Ethics in Science and New Technologies
The European Commission appointed the 15 new members of the new European Group on Ethics in Science and New Technologies (EGE).
You are here: vision-research.eu » News
The European Commission appointed the 15 new members of the new European Group on Ethics in Science and New Technologies (EGE).
Severe visual illnesses are increasing in our society, and effective treatments are missing for diseases as age-related macular degeneration, diabetic retinopathy, and glaucoma. Both industry and academia are highly interested to advance ocular drug discovery and development. Ocular pharmacokinetics is a key science in this process, and knowledge of drug metabolism and distribution in the eye is required.
Efforts to chart and reduce bias in scholarly publishing will ask authors, reviewers and editors to disclose their race or ethnicity.
Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken during a routine visit to an optician or eye clinic and identify patients at a high risk of a heart attack.
The first robotic gonio surgery system was developed in the heat of the pandemic in 2020 by the ophthalmology innovation team at New York Eye and Ear Infirmary of Mount Sinai in New York, New York.
Evis Kushi, Minister of Education and Sports of Albania signed, alongside Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, their Association Agreements to the Horizon Europe programme. This marks an important milestone for closer research and innovation cooperation with the Western Balkans.
New research has laid the groundwork for a long-lasting eye drop to treat corneal neovascularisation (CoNV), a condition which affects more than a million people globally each year.
National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt, an eye disease that can lead to childhood vision loss.
PolyActiva Pty Ltd. announced that the Phase IIa study of its PA5108 ocular implant for the treatment of primary open-angle glaucoma (POAG) met both the study's primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort.
As part of the Global Gateway Investment Package, the Innovation Agenda has four main objectives: translate innovative capacities and results into tangible outputs; strengthen innovation ecosystems; develop sustainable and mutually beneficial higher education and R&I partnerships; scale-up instruments and programmes that can take forward existing successful initiatives.
Scientific collaboration has become a casualty of Switzerland’s and the United Kingdom’s tussles with the European Union.
Developing therapies for genetic forms of blindness is extremely challenging, in part because they vary so widely, but scientists from Trinity College Dublin have highlighted a target with great promise for treating a range of these conditions.
The company will use proceeds from the Series A to assemble and develop a diversified pipeline of product candidates that combines scientifically compelling targets with innovative translational approaches.
Researchers say that conflict will hinder progress made since Ukraine’s revolution in 2014.
The journal Biomedical Optics Express, published by Optica (formerly OSA), announced a special issue on “Adaptive Optics for Biomedical Applications.”